Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 5/2018

01-05-2018 | Original Research Article

Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation

Authors: Kana Mizuno, Min Dong, Tsuyoshi Fukuda, Sharat Chandra, Parinda A. Mehta, Scott McConnell, Elias J. Anaissie, Alexander A. Vinks

Published in: Clinical Pharmacokinetics | Issue 5/2018

Login to get access

Abstract

Background

High-dose melphalan is an important component of conditioning regimens for patients undergoing hematopoietic stem cell transplantation. The current dosing strategy based on body surface area results in a high incidence of oral mucositis and gastrointestinal and liver toxicity. Pharmacokinetically guided dosing will individualize exposure and help minimize overexposure-related toxicity.

Objective

The purpose of this study was to develop a population pharmacokinetic model and optimal sampling strategy.

Methods

A population pharmacokinetic model was developed with NONMEM using 98 observations collected from 15 adult patients given the standard dose of 140 or 200 mg/m2 by intravenous infusion. The determinant-optimal sampling strategy was explored with PopED software. Individual area under the curve estimates were generated by Bayesian estimation using full and the proposed sparse sampling data. The predictive performance of the optimal sampling strategy was evaluated based on bias and precision estimates. The feasibility of the optimal sampling strategy was tested using pharmacokinetic data from five pediatric patients.

Results

A two-compartment model best described the data. The final model included body weight and creatinine clearance as predictors of clearance. The determinant-optimal sampling strategies (and windows) were identified at 0.08 (0.08–0.19), 0.61 (0.33–0.90), 2.0 (1.3–2.7), and 4.0 (3.6–4.0) h post-infusion. An excellent correlation was observed between area under the curve estimates obtained with the full and the proposed four-sample strategy (R 2 = 0.98; p < 0.01) with a mean bias of −2.2% and precision of 9.4%. A similar relationship was observed in children (R 2 = 0.99; p < 0.01).

Conclusions

The developed pharmacokinetic model-based sparse sampling strategy promises to achieve the target area under the curve as part of precision dosing.
Appendix
Available only for authorised users
Literature
1.
Marsh RA, Vaughn G, Kim MO, Li DD, Jodele S, Joshi S, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010;116(26):5824–31.CrossRefPubMed
2.
Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006;107(7):2633–8.CrossRefPubMed
3.
Marsh R, Fukuda T, Emoto C, Neumeier L, Khandelwal P, Chandra S, et al. Pre-transplant absolute lymphocyte counts impact the pharmacokinetics of alemtuzumab. Biol Blood Marrow Tranplant. 2017;23(4):635–41.CrossRef
4.
Shaw PJ, Nath CE, Lazarus HM. Not too little, not too much-just right! (Better ways to give high dose melphalan). Bone Marrow Transplant. 2014;49(12):1457–65.CrossRefPubMed
5.
Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N, et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant. 2006;38(7):501–6.CrossRefPubMed
6.
Blijlevens N, Schwenkglenks M, Bacon P, D’Addio A, Einsele H, Maertens J, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy: European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol. 2008;26(9):1519–25.CrossRefPubMed
7.
Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99(3):731–5.CrossRefPubMed
8.
Peterman A, Cella D, Glandon G, Dobrez D, Yount S. Mucositis in head and neck cancer: economic and quality-of-life outcomes. J Natl Cancer Instit Monogr. 2001;29:45–51.CrossRef
9.
Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19(8):2201–5.CrossRefPubMed
10.
Shaw PJ, Nath CE, Nivison-Smith I, Joshua DE, Kerridge IH, Presgrave P, et al. Higher melphalan exposure is associated with improved overall survival for myeloma patients undergoing autologous transplant. Biol Blood Marrow Transplant. 2012;18(2):S207.CrossRef
11.
Ploin DY, Tranchand B, Guastalla JP, Rebattu P, Chauvin F, Clavel M, et al. Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma. Eur J Cancer. 1992;28A(8–9):1311–5.CrossRefPubMed
12.
Kuhne A, Sezer O, Heider U, Meineke I, Muhlke S, Niere W, et al. Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. Clin Pharmacol Ther. 2008;83(5):749–57.CrossRefPubMed
13.
Nath CE, Shaw PJ, Trotman J, Zeng LH, Duffull SB, Hegarty G, et al. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Br J Clin Pharmacol. 2010;69(5):484–97.CrossRefPubMedPubMedCentral
14.
Nath CE, Trotman J, Tiley C, Presgrave P, Joshua D, Kerridge I, et al. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. Br J Clin Pharmacol. 2016;82(1):149–59.CrossRefPubMedPubMedCentral
15.
Jelliffe RW, Schumitzky A, Van Guilder M, Liu M, Hu L, Maire P, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit. 1993;15(5):380–93.CrossRefPubMed
16.
Mould DR, D’Haens G, Upton RN. Clinical decision support tools: the evolution of a revolution. Clin Pharmacol Ther. 2016;99(4):405–18.CrossRefPubMed
17.
Tesfaye H, Branova R, Klapkova E, Prusa R, Janeckova D, Riha P, et al. The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children. Ann Transplant. 2014;19:214–24.CrossRefPubMed
18.
Philippe M, Neely M, Bertrand Y, Bleyzac N, Goutelle S. A nonparametric method to optimize initial drug dosing and attainment of a target exposure interval: concepts and application to busulfan in pediatrics. Clin Pharmacokinet. 2017;56(4):435–47.CrossRefPubMed
19.
Neely M, Philippe M, Rushing T, Fu X, van Guilder M, Bayard D, et al. Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the BestDose software. Ther Drug Monit. 2016;38(3):332–42.CrossRefPubMedPubMedCentral
20.
Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016;3(11):e526–36.CrossRefPubMedPubMedCentral
21.
Abdel-Rahman SM, Breitkreutz ML, Bi C, Matzuka BJ, Dalal J, Casey KL, et al. Design and testing of an EHR-integrated, busulfan pharmacokinetic decision support tool for the point-of-care clinician. Front Pharmacol. 2016;7:65.CrossRefPubMedPubMedCentral
22.
McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NH. Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res. 2014;20(3):754–63.CrossRefPubMed
23.
Tranchand B, Ploin YD, Minuit MP, Sapet C, Biron P, Philip T, et al. High-dose melphalan dosage adjustment: possibility of using a test-dose. Cancer Chemother Pharmacol. 1989;23(2):95–100.CrossRefPubMed
24.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.CrossRefPubMed
25.
Nath CE, Zeng L, Eslick A, Trotman J, Earl JW. An isocratic UV HPLC assay for analysis of total and free melphalan concentrations in human plasma. Acta Chromatogr. 2008;20(3):383–98.CrossRef
26.
Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user’s guides (1989–2009). Ellicott City: Icon Development Solutions; 2009.
27.
Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometr Syst Pharmacol. 2013;2:e50.CrossRef
28.
Choi L, Caffo BS, Kohli U, Pandharipande P, Kurnik D, Ely EW, et al. A Bayesian hierarchical nonlinear mixture model in the presence of artifactual outliers in a population pharmacokinetic study. J Pharmacokinet Pharmacodyn. 2011;38(5):613–36.CrossRefPubMedPubMedCentral
29.
Nath CE, Shaw PJ, Montgomery K, Earl JW. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Br J Clin Pharmacol. 2007;64(2):151–64.CrossRefPubMedPubMedCentral
30.
Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, et al. Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial. Clin Pharmacol Ther. 2017;. doi:10.​1002/​cpt.​644 (Epub ahead of print).
31.
Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Ann Rev Pharmacol Toxicol. 2008;48:303–32.CrossRef
32.
Mould DR, Holford NH, Schellens JH, Beijnen JH, Hutson PR, Rosing H, et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther. 2002;71(5):334–48.CrossRefPubMed
33.
Jonsson EN, Karlsson MO. Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58(1):51–64.CrossRefPubMed
34.
Wang Y, Jadhav PR, Lala M, Gobburu JV. Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies. J Clin Pharmacol. 2012;52(10):1601–6.CrossRefPubMed
35.
Mouksassi M, Marier J, Cyran J, Vinks A. Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome. Clin Pharmacol Ther. 2009;86(6):667–71.CrossRefPubMed
36.
Foracchia M, Hooker A, Vicini P, Ruggeri A. POPED, a software for optimal experiment design in population kinetics. Comput Methods Programs Biomed. 2004;74(1):29–46.CrossRefPubMed
37.
Ogungbenro K, Aarons L. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments. J Biopharm Stat. 2009;19(1):174–89.CrossRefPubMed
38.
D’Argenio DZ, Schumitzky A, Wang X. ADAPT 5 user’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles: Biomedical Simulations Resource; 2009.
39.
D’Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm. 1981;9(6):739–56.CrossRefPubMed
40.
Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503–12.CrossRefPubMed
41.
Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med. 1992;22(3):155–63.CrossRefPubMed
42.
Ardiet C, Tranchand B, Biron P, Rebattu P, Philip T. Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis: report in 26 cases. Cancer Chemother Pharmacol. 1986;16(3):300–5.CrossRefPubMed
43.
Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet. 2013;52(1):9–22.CrossRefPubMed
44.
Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498–509.CrossRefPubMedPubMedCentral
45.
Wojciechowski J, Hopkins AM, Upton RN. Interactive pharmacometric applications using R and the Shiny Package. CPT Pharmacometr Syst Pharmacol. 2015;4(3):e00021.CrossRef
46.
Mougenot P, Pinguet F, Fabbro M, Culine S, Poujol S, Astre C, et al. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. Cancer Chemother Pharmacol. 2004;53(6):503–12.CrossRefPubMed
47.
Reece PA, Hill HS, Green RM, Morris RG, Dale BM, Kotasek D, et al. Renal clearance and protein binding of melphalan in patients with cancer. Cancer Chemother Pharmacol. 1988;22(4):348–52.CrossRefPubMed
48.
Cornwell GG 3rd, Pajak TF, McIntyre OR, Kochwa S, Dosik H. Influence of renal failure on myelosuppressive effects of melphalan: cancer and leukemia group B experience. Cancer Treat Rep. 1982;66(3):475–81.PubMed
49.
Bolton MG, Colvin OM, Hilton J. Specificity of isozymes of murine hepatic glutathione S-transferase for the conjugation of glutathione with l-phenylalanine mustard. Cancer Res. 1991;51(9):2410–5.PubMed
50.
Dirven HA, van Ommen B, van Bladeren PJ. Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases. Chem Res Toxicol. 1996;9(2):351–60.CrossRefPubMed
51.
Bredschneider M, Klein K, Murdter TE, Marx C, Eichelbaum M, Nussler AK, et al. Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. Clin Pharmacol Ther. 2002;71(6):479–87.CrossRefPubMed
52.
Kim SD, Lee JH, Hur EH, Lee JH, Kim DY, Lim SN, et al. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(8):1222–30.CrossRefPubMed
53.
Elhasid R, Krivoy N, Rowe JM, Sprecher E, Adler L, Elkin H, et al. Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2010;55(6):1172–9.CrossRefPubMed
54.
Ansari M, Lauzon-Joset JF, Vachon MF, Duval M, Theoret Y, Champagne MA, et al. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transplant. 2010;45(2):261–7.CrossRefPubMed
55.
Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M, et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004;104(5):1574–7.CrossRefPubMed
56.
Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol. 1995;13(7):1786–99.CrossRefPubMed
57.
Krishna SG, Zhao W, Grazziutti ML, Sanathkumar N, Barlogie B, Anaissie EJ. Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients: clinical and research implications. Cancer. 2011;117(3):648–55.CrossRefPubMed
58.
Aljitawi OS, Ganguly S, Abhyankar SH, Ferree M, Marks R, Pipkin JD, et al. Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation. Bone Marrow Transplant. 2014;49(8):1042–5.CrossRefPubMed
Metadata
Title
Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation
Authors
Kana Mizuno
Min Dong
Tsuyoshi Fukuda
Sharat Chandra
Parinda A. Mehta
Scott McConnell
Elias J. Anaissie
Alexander A. Vinks
Publication date
01-05-2018
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 5/2018
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-017-0581-x

Other articles of this Issue 5/2018

Clinical Pharmacokinetics 5/2018 Go to the issue

Original Research Article

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial

Author Correction

Author Correction: Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?

Review Article

Population Pharmacokinetics of Mycophenolic Acid: An Update

Original Research Article

Improving Pediatric Protein Binding Estimates: An Evaluation of α1-Acid Glycoprotein Maturation in Healthy and Infected Subjects

Review Article

Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones

Original Research Article

Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials